Literature DB >> 33295867

Genomic epidemiology of Escherichia coli isolates from a tertiary referral center in Lilongwe, Malawi.

Gerald Tegha1, Emily J Ciccone2, Robert Krysiak1, James Kaphatika1, Tarsizio Chikaonda1, Isaac Ndhlovu3, David van Duin2, Irving Hoffman2, Jonathan J Juliano4,5,2, Jeremy Wang6.   

Abstract

Antimicrobial resistance (AMR) is a global threat, including in sub-Saharan Africa. However, little is known about the genetics of resistant bacteria in the region. In Malawi, there is growing concern about increasing rates of antimicrobial resistance to most empirically used antimicrobials. The highly drug resistant Escherichia coli sequence type (ST) 131, which is associated with the extended spectrum β-lactamase blaCTX-M-15, has been increasing in prevalence globally. Previous data from isolates collected between 2006 and 2013 in southern Malawi have revealed the presence of ST131 and the blaCTX-M-15 gene in the country. We performed whole genome sequencing (WGS) of 58 clinical E. coli isolates at Kamuzu Central Hospital, a tertiary care centre in central Malawi, collected from 2012 to 2018. We used Oxford Nanopore Technologies (ONT) sequencing, which was performed in Malawi. We show that ST131 is observed more often (14.9% increasing to 32.8%) and that the blaCTX-M-15 gene is occurring at a higher frequency (21.3% increasing to 44.8%). Phylogenetics indicates that isolates are highly related between the central and southern geographic regions and confirms that ST131 isolates are contained in a single group. All AMR genes, including blaCTX-M-15, were widely distributed across sequence types. We also identified an increased number of ST410 isolates, which in this study tend to carry a plasmid-located copy of blaCTX-M-15 gene at a higher frequency than blaCTX-M-15 occurs in ST131. This study confirms the expanding nature of ST131 and the wide distribution of the blaCTX-M-15 gene in Malawi. We also highlight the feasibility of conducting longitudinal genomic epidemiology studies of important bacteria with the sequencing done on site using a nanopore platform that requires minimal infrastructure.

Entities:  

Keywords:  Africa; Escherichia coli; Malawi; antimicrobial resistance; molecular epidemiology; whole genome sequencing

Year:  2021        PMID: 33295867      PMCID: PMC8115906          DOI: 10.1099/mgen.0.000490

Source DB:  PubMed          Journal:  Microb Genom        ISSN: 2057-5858


Data Summary

The sequencing data used for this analysis is available in public data repositories. Information on the newly generated data is available in NCBI SRA (BioProject ID PRJNA635644). Other publicly available sequences used are provided in Table S2. Antimicrobial resistance is a global public health emergency. Although rates of resistance are high in Africa, little is known about the genetics and resistance mechanisms of clinically important bacteria. Here we characterize the molecular epidemiology of isolates from a tertiary referral hospital in Malawi and compare these with historical isolates from the same country. Consistent with their global expansion, we show that ST131 is observed more often and that the bla gene is occurring at a higher frequency between studies. However, phylogenetics indicates that isolates are highly related between the central and southern geographic regions. This study highlights the feasibility of conducting longitudinal genomic epidemiology studies of important bacteria with the sequencing done on site using a nanopore platform that requires minimal infrastructure.

Introduction

Antimicrobial resistance (AMR) is one of the most serious global public health threats [1]. Of specific concern are (formerly the Enterobacteriaceae) that are resistant to third-generation cephalosporins such as ceftriaxone. The World Health Organization (WHO) has designated ceftriaxone-resistant as a critical priority [2]. In sub-Saharan Africa (SSA), there is growing evidence that ceftriaxone-resistant are important pathogens in invasive infections such as bacteremia. Given that ceftriaxone is often used to treat severe infections in SSA, and carbapenems are not often available, this is a major concern. Among the , () is a common cause of invasive disease, accounting for between 3 and 33 % of positive blood cultures in case series in Africa [3-8]. is becoming more resistant to commonly used antibiotics in SSA, including ceftriaxone. Additionally, recent evidence indicates that the highly drug resistant sequence type (ST) 131 has been increasing in prevalence globally [9-11]. This sequence type is an extraintestinal pathogenic (ExPEC) that is associated with bloodstream and urinary tract infections, often possessing genes associated with extended-spectrum β-lactamases (ESBLs) [12, 13]. The main mechanism of cephalosporin resistance is drug inactivation mediated by hydrolysis of the β-lactam ring by ESBL enzymes. Cefatoxamine-resistance Munich (CTX-M) derivatives are the dominant and most widely distributed ESBL enzymes among [14]. CTX-M-15 is strongly associated with ST131 [15-18]. The global spread of ESBL- is largely attributed to the dissemination of strains carrying the bla gene, especially O25b:H4-ST131 [11]. Previously, three major lineages of ST131 have been identified that differed mainly with respect to their fimH alleles: A (mainly fimH41), B (mainly fimH22) and C (mainly fimH30) [19]. Clade C has predominated since the 2000s, corresponding with the rapid dissemination of the bla allele [11, 19, 20]. There is growing evidence in SSA that ST 131 CTX-M-15 strains are increasing, but there remains a limited number of studies assessing the clonality of E.coli, the distribution of ST131 and the presence of bla genes using whole genome sequencing [21-24]. In Malawi, specifically, there has been growing concern about increasing rates of antimicrobial resistance to most empirically used antimicrobials [25, 26]. A recent genomic epidemiology study of 94 isolates collected at Queen Elizabeth Central Hospital, a tertiary care centre in southern Malawi, and analysed by whole genome sequencing (WGS), has shown that ST131 is the most common ST in southern Malawi at 14.9% of isolates sequenced. CTX-M-15 was found in 21.4% of ST131 isolates, but occurred across 11 STs [27]. The purpose of our study is to increase our understanding of the genomic epidemiology of in Malawi by conducting WGS, using Oxford Nanopore Technologies (ONT) sequencing performed in Malawi, of isolates collected at a tertiary care hospital in central Malawi. We use this data to define the clonality, virulence genes and antimicrobial resistance genes in the central region of the country and to compare these results with those for southern Malawi.

Methods

Sample selection

Sixty isolates were selected from the UNC Project-Malawi archives for sequencing. Samples were collected between 2012 and 2018. Organisms were isolated using sheep blood agar (trypticase soy agar prepared with 5% defibrinated sheep blood) and MacConkey agar (selective and differential medium for Gram-negative rods) as primary culture media. Depending on the year of sample collection, identification was done either using conventional biochemical tests (TSI, indole, citrate and urease) and or Analytical Profile Index (API) 20E, a biochemical panel for identification and differentiation of members of the family Enterobacteriaceae. Isolates were selected for this study on the basis of diversity of phenotypic resistance pattern and clinical source of isolation, similarly to a previous study in Malawi [27]. One isolate was excluded from further analysis due to poor sequencing coverage, and one was excluded as it was identified as , resulting in 58 isolates included in all analyses.

Antimicrobial resistance testing

The Kirby-Bauer disc diffusion method was used to measure the in vitro susceptibility of bacteria to antimicrobial agents at the UNC Project-Malawi microbiology laboratory at the time of isolate collection. Results were obtained with disc diffusion tests that use the principle of standardized methodology and zone diameter measurements correlated with minimum inhibitory concentrations (MICs) with strains known to be susceptible, intermediate, and resistant to various antibiotics. All aspects of the procedure were standardized as recommended by the Clinical and Laboratory Standards Institute (CLSI) in the document ‘Performance Standards for Antimicrobial Susceptibility Testing’ [28].

Whole genome sequencing

Overnight cultures of the isolates were grown in 5 ml of LB broth at 37 °C. Cell pellets from the broth culture were recovered from 1.5 ml centrifuged at 10 000 for 2 min. Cell pellets were resuspended in 100 µl of nuclease-free water. DNA was extracted from the resuspended pellet using the Zymo Quick-DNA Microprep Kit (cell suspensions protocol) as per the manufacturer’s instructions (Zymo Research). The DNA was quantified using the dsDNA kit on a Qubit 2.0 (Thermo Fisher). Equal amounts of DNA (~100 ng) from each isolate were used for library preparation using the Rapid Barcoding (RBK-004) as per the manufacturer’s protocol (Oxford Nanopore Technologies). Pooled libraries of 12 isolates were run on a R9.4.1 flow cell on a MinION/MinIT for 24 h at UNC Project-Malawi. Each flow cell was washed once per protocol and a second set of 12 isolates were run for an additional 24 h or until all pores were exhausted.

De novo genome assembly

Base calling of fast5 files was done with Guppy (version 3.4.5) with the R9.4.1 ‘high accuracy’ model [29]. Samples were demultiplexed and adapters/barcodes trimmed using a custom tool, depore (version 0.1; https://github.com/txje/depore). Reads for each isolate were de novo assembled using Flye (version 2.7) [30]. By Flye’s design and empirically [31], chimeric reads should not affect assembly performance and are much less prevalent in rapid (transposase-based) as opposed to ligation-based library preparation [32]. Assemblies were then polished four times with racon (version 1.3.2) and underwent a final polish with medaka (version 0.6.2) (http://github.com/nanoporetech/medaka) [33, 34].

Typing of isolates

Each assembly was aligned using minimap2 to databases of known serotypes, fimH type, genomic and plasmid sequence types including plasmid incompatibility, virulence factors, and antimicrobial resistance genes, listed in Table S1 (available in the online version of this article) [35-40]. Matches were made for each assembly using similar cutoffs to those used by the Centre for Genomic Epidemiology (CGE; https://cge.cbs.dtu.dk/services/data.php) tools. Specifically, we required 60% of the feature to match at >90% sequence identity to serotype markers (fliC, wzx/wzy), fimH variant, virulence genes, antimicrobial resistance genes, and plasmid incompatibility group markers. For multi-locus sequence type (MLST) and fimH type, we report the closest hit (or multiple hits in case of a tie). Assembled contigs were identified as plasmids if they were found to contain at least one plasmid incompatibility type marker. For bla analysis, contigs >600 kbp without plasmid markers are inferred to be genomic, in all but two cases they are ~5 Mbp. No plasmid markers were found on any contig >300 kbp.

Species identification

We detected O and/or H serotypes and multi-locus sequence types in 59 of 60 presumed samples. The remaining sample appeared to have assembled well and a blast search revealed it was a strain of . We used this sequence as an outgroup in our phylogenetic analysis and otherwise excluded it from further analysis. An additional isolate (#31) was excluded from analysis for poor sequencing coverage, leaving 58 samples for all downstream analyses.

Phylogenomics

Assembled genomes were aligned to a set of single-copy orthologs largely conserved across (BUSCO v4, https://busco.ezlab.org/). A subset of 92 genes were selected that appear in all 58 samples that were included in the final analysis. A multiple-sequence alignment was performed for each gene using muscle (3.8.31) [41]. This concatenated alignment includes 108 278 sites, 16 729 informative SNPs. RAxML-ng was used to reconstruct a maximum-likelihood phylogenetic tree for the concatenated alignments with model parameter ‘GTR+G’ (Fig. 1) [42]. For the comparison to existing Malawi isolates, we used publicly available sequence data listed in Table S2. For each of these samples, a genome was assembled from Illumina sequence data with SPAdes (3.14.0) using default parameters [43]. A phylogeny incorporating these sequences was generated as described above, using a subset of 80 genes present in all 149 genomes (Fig. 2). This 92 gene alignment includes 125 994 sites and 18 282 informative SNPs. To evaluate the accuracy of these phylogenies based on a limited set of highly conserved genes in representing the global genomic phylogeny, we generated a more liberal ‘core’ gene alignment using Roary [44] that captures a much larger portion of the genome and found few differences (Supplemental Methods, Figures S1 and S2).
Fig. 1.

Distribution of sequence type, specimen type, resistance phenotype and resistance gene composition in 58 Malawian Isolates. Phylogenetic relationship among sequenced isolates with corresponding sequence type, specimen type, phenotypic and genomic AMR status. At the far left is the phylogeny relating these 58 samples with the sequenced from our study as an outgroup (not shown). In line with each terminal branch is the corresponding sample’s sequence type (ST) (‘AMB’ indicates ambiguity in ST assignment), specimen from which the sample was isolated, AMR phenotype (red: resistant, blue: susceptible, purple: intermediate, grey: unknown), and presence of each detected AMR gene in the genome assembly (dark grey: present, light grey: absent, red highlights presence of bla).

Fig. 2.

Phylogenetic tree of Malawian isolates. Phylogenetic relationships among the 58 isolates are presented here in relation to previously published Malawi isolates (Table S2). Samples cluster by sequence type, but are well mixed between the two geographically and temporally separated studies. In the left column, blue indicates isolates from this study and grey from the previous study [17]. The rightmost column indicates the MLST where sequence types occurring more than once are assigned a unique colour (all others are left grey).

Distribution of sequence type, specimen type, resistance phenotype and resistance gene composition in 58 Malawian Isolates. Phylogenetic relationship among sequenced isolates with corresponding sequence type, specimen type, phenotypic and genomic AMR status. At the far left is the phylogeny relating these 58 samples with the sequenced from our study as an outgroup (not shown). In line with each terminal branch is the corresponding sample’s sequence type (ST) (‘AMB’ indicates ambiguity in ST assignment), specimen from which the sample was isolated, AMR phenotype (red: resistant, blue: susceptible, purple: intermediate, grey: unknown), and presence of each detected AMR gene in the genome assembly (dark grey: present, light grey: absent, red highlights presence of bla). Phylogenetic tree of Malawian isolates. Phylogenetic relationships among the 58 isolates are presented here in relation to previously published Malawi isolates (Table S2). Samples cluster by sequence type, but are well mixed between the two geographically and temporally separated studies. In the left column, blue indicates isolates from this study and grey from the previous study [17]. The rightmost column indicates the MLST where sequence types occurring more than once are assigned a unique colour (all others are left grey).

Data analysis

Data were analysed using STATA/SE version 16.1 (StataCorp LLC, College Station, TX, USA). Descriptive statistics were used to describe clinical characteristics, frequencies of gene detections, and disc diffusion results. Given the small overall sample size, two-sided Fisher’s exact tests were used to assess for associations between genes detected and phenotypic resistance testing by Kirby–Bauer disc diffusion. P-values were corrected for multiple comparisons using the Benjamini–Hochberg false discovery rate method [45].

Results

Isolate characteristics and sequencing data

Five sequencing runs generated 9 291492 reads totalling 40.8 Gbp with a mean read length of 4391 bp and N50 of 8732 bp. Sequencing summary statistics across samples are described in Table 1. Clinical and patient characteristics for the isolates are summarized in Table 2. The majority were from a urinary source (59%) and were from females (74%). A significant number of isolates were from sterile sites, including blood (24%), cerebrospinal fluid (3%), and joint (3%). Patient white blood cell counts and haemoglobin levels were available for 20 of the isolates; medians and interquartile ranges are included in Table 2.
Table 1.

Sequence data characteristics of all sequenced isolates

Sequence data

Value*

Number of reads

126 886 (21 843–539 714)

Total bps

556 Mbp (84–2076 Mbp)

Median fragment size sequenced in sample

2505 bp (673–4560 bp)

N50 assembly

4.88 Mbp (0.59–5.37 Mbp)

Number of contigs

5 (1–43)

Chromosomal median coverage

106 (15–392)

*Median (Minimum, Maximum).

Table 2.

Patient characteristics of the 58 included isolates

Variable

Number of isolates

n (%)

Sex

 Female

43 (74)

 Male

15 (26)

Age*

34 (20–47)

Sample Type

 Blood

14 (24)

 Urine

34 (59)

 CSF

2 (3)

 Body Fluid

2 (3)

 Joint

2 (3)

 Other

4 (7)

Lab Values†

White blood cell count (cells µl−1)

7.5 (3.8–9.1)

Haemoglobin (g dl−1)

9.8 (8.4–11.6)

*Median (IQR); data available for 54 patients.

†Median (IQR); data available for 20 patients.

Sequence data characteristics of all sequenced isolates Sequence data Value* Number of reads 126 886 (21 843–539 714) Total bps 556 Mbp (84–2076 Mbp) Median fragment size sequenced in sample 2505 bp (673–4560 bp) N50 assembly 4.88 Mbp (0.59–5.37 Mbp) Number of contigs 5 (1–43) Chromosomal median coverage 106 (15–392) *Median (Minimum, Maximum). Patient characteristics of the 58 included isolates Variable Number of isolates n (%) Sex Female 43 (74) Male 15 (26) Age* 34 (20–47) Sample Type Blood 14 (24) Urine 34 (59) CSF 2 (3) Body Fluid 2 (3) Joint 2 (3) Other 4 (7) Lab Values† White blood cell count (cells µl−1) 7.5 (3.8–9.1) Haemoglobin (g dl−1) 9.8 (8.4–11.6) *Median (IQR); data available for 54 patients. †Median (IQR); data available for 20 patients. Kirby–Bauer antimicrobial susceptibility testing results are summarized in Table 3. Notably, the majority of isolates were resistant to amoxicillin and trimethoprim–sulfamethoxazole (TMP–SMX) and 57 % (33/58) were resistant to ceftriaxone. These are commonly prescribed antibiotics in the outpatient (amoxicillin and TMP–SMX) and inpatient (ceftriaxone) settings in Malawi [46].
Table 3.

Kirby–Bauer antimicrobial resistance patterns of included isolates*

Drug (Total Tested)

Susceptible, n (%)

Intermediate, n (%)†

Resistant, n (%)

Amox-Clav (56)

15 (27)

9 (16)

32 (57)

Amoxicillin (58)

3 (5)

1 (2)

54 (93)

Cefotaxime (49)

21 (43)

0 (0)

28 (57)

Ceftriaxone (58)

25 (43)

0 (0)

33 (57)

Chloramphenicol (48)

29 (60)

4 (8)

15 (31)

Ciprofloxacin (58)

21 (36)

2 (3)

35 (60)

Gentamicin (57)

30 (53)

0 (0)

27 (47)

Imipenem (31)

31 (100)

0 (0)

0 (0)

Nalidixic Acid (57)

17 (30)

2 (4)

38 (67)

TMP-SMX (50)

4 (8)

1 (2)

45 (90)

*Percentage may not equal 100% due to rounding.

†Intermediate susceptibility by Kirby–Bauer test is defined based on a breakpoint that includes isolates with ‘zone diameters within the intermediate range that approach usually attainable blood and tissue levels.’ Response rates may be lower than for susceptible isolates; it implies clinical efficacy in sites where drugs physiologically concentrate or when a higher-than-normal dosage of a drug is used.

Kirby–Bauer antimicrobial resistance patterns of included isolates* Drug (Total Tested) Susceptible, n (%) Intermediate, n (%)† Resistant, n (%) Amox-Clav (56) 15 (27) 9 (16) 32 (57) Amoxicillin (58) 3 (5) 1 (2) 54 (93) Cefotaxime (49) 21 (43) 0 (0) 28 (57) Ceftriaxone (58) 25 (43) 0 (0) 33 (57) Chloramphenicol (48) 29 (60) 4 (8) 15 (31) Ciprofloxacin (58) 21 (36) 2 (3) 35 (60) Gentamicin (57) 30 (53) 0 (0) 27 (47) Imipenem (31) 31 (100) 0 (0) 0 (0) Nalidixic Acid (57) 17 (30) 2 (4) 38 (67) TMP-SMX (50) 4 (8) 1 (2) 45 (90) *Percentage may not equal 100% due to rounding. †Intermediate susceptibility by Kirby–Bauer test is defined based on a breakpoint that includes isolates with ‘zone diameters within the intermediate range that approach usually attainable blood and tissue levels.’ Response rates may be lower than for susceptible isolates; it implies clinical efficacy in sites where drugs physiologically concentrate or when a higher-than-normal dosage of a drug is used.

Sequence types, H and O groups

Twenty-one different ST groups were found among 53 isolates. Five isolates could not be assigned to a unique ST group (Table S3). ST131 was the most common type identified [19 of 58 isolates (32.8%)], followed by ST410 which was present in 9 of 58 isolates (15.5%). Other STs that occurred in more than one isolate included ST69 (5.2%), ST38 (3.4%), ST617 (5.2%) and ST12 (3.4%). Of the 19 ST131, 18 of them were fimH30 and therefore clade C. One isolate was fimH27 and classified as clade B0. The fimH30 was linked to O25 and O16, while the fimH27 strain was O18 but also ST131. The population contained 23 different O groups (Table S4), with three samples being unable to be called, and 17 different H group calls (Table S5). A complete data set of genotype calls and sequencing characteristics is available in Table S6.

Population structure of in Malawi

A phylogenetic tree of the isolates with previously reported i genomes from southern Malawi [27] is shown in Fig. 2. Notably, the ST131 isolates cluster into a single group and have relatively little genetic distance between them in the tree.

Genetic determinants of antimicrobial resistance

Our analysis identified 69 unique AMR genes that are known to encode proteins associated with antimicrobial susceptibility across a range of compounds (Table 4). AMR genes occurred across a range of ST and phylogenetic groups (Fig. 1).
Table 4.

Prevalence of AMR genes identified

Gene

Resistance Phenotype

Isolates, n (%)

Aminoglycoside Resistance

aac(3)-IIa

Gentamicin

11 (19)

aac(3)-IId

Gentamicin

15 (26)

aac(6′)−30

Aminoglycoside

2 (3)

aac(6')-Ib-cr6

Amikacin, kanamycin, tobramycin, quinolone

1 (2)

aadA1

Streptomycin

6 (10)

aadA2

Streptomycin

2 (3)

aadA5

Streptomycin

34 (59)

ant(3'')-Ih

Streptomycin/spectinomycin

20 (34)

aph(3'')-Ib

Streptomycin

5 (9)

aph(3')-Ia

Kanamycin

2 (3)

aph(6)-Id

Streptomycin

50 (86)

strA

Streptomycin

50 (86)

strB

Streptomycin

50 (86)

Multidrug Efflux Pumps

acrF

Multidrug efflux

58 (100)

emrD

Multidrug efflux

58 (100)

emrE

Multidrug efflux

6 (10)

mdtM

Multidrug efflux

46 (79)

β-lactam Resistance

blaCMY-18

Cephalosporin

6 (10)

blaCTX-M-15

Cephalosporin

26 (45)

blaCTX-M-155

Cephalosporin

1 (2)

blaCTX-M-159

Cephalosporin

1 (2)

blaCTX-M-182

Cephalosporin

1 (2)

blaCTX-M-27

Cephalosporin

3 (5)

blaCTX-M-3

Cephalosporin

1 (2)

blaEC-15

Cephalosporin

20 (34)

blaEC-18

Cephalosporin

2 (3)

blaEC-19

Cephalosporin

23 (40)

blaEC-5

Cephalosporin

7 (12)

blaEC-8

Cephalosporin

3 (5)

blaEC

β-lactam

3 (5)

blaLAP-2

β-lactam

4 (7)

blaOXA-1

Cephalosporin

21 (36)

blaOXA-10

Cephalosporin

2 (3)

blaOXA-9

β-lactam

2 (3)

blaTEM-1

β-lactam

43 (74)

blaTEM-113

Cephalosporin

1 (2)

blaTEM-150

β-lactam

1 (2)

blaTEM-209

β-lactam

2 (3)

blaTEM-214

β-lactam

1 (2)

blaTEM-235

β-lactam

1 (2)

Chloramphenicol Resistance

catA1

Chloramphenicol

11 (19)

catA2

Chloramphenicol

2 (3)

catB3

Chloramphenicol

21 (36)

cmlA

Chloramphenicol

1 (2)

cmlA1

Chloramphenicol

1 (2)

cmlA5

Chloramphenicol

2 (3)

TMP/SMX Resistance

dfrA1

Trimethoprim

2 (3)

dfrA12

Trimethoprim

2 (3)

dfrA14

Trimethoprim

9 (16)

dfrA15

Trimethoprim

1 (2)

dfrA17

Trimethoprim

35 (60)

dfrA5

Trimethoprim

1 (2)

dfrA7

Trimethoprim

4 (7)

dfrA8

Trimethoprim

8 (14)

sul1

Sulfonamide

39 (67)

sul2

Sulfonamide

51 (88)

sul3

Sulfonamide

1 (2)

Quinolone Resistance

qnrB1

Quinolone

1 (2)

qnrS1

Quinolone

5 (9)

Other Antimicrobials

arr-2

Rifamycin

2 (3)

aar-3

Rifamycin

1 (2)

erm(B)

Macrolide

1 (2)

fosA3

Fosfomycin

1 (2)

mph(A)

Macrolide

37 (64)

mph(B)

Macrolide

1 (2)

qacL

Quaternary Ammonium

1 (2)

sat2_gen

Streptothricin

2 (3)

tet(A)

Tetracycline

30 (52)

tet(B)

Tetracycline

21 (36)

Prevalence of AMR genes identified Gene Resistance Phenotype Isolates, n (%) Aminoglycoside Resistance aac(3)-IIa Gentamicin 11 (19) aac(3)-IId Gentamicin 15 (26) aac(6′)−30 Aminoglycoside 2 (3) aac(6')-Ib-cr6 Amikacin, kanamycin, tobramycin, quinolone 1 (2) aadA1 Streptomycin 6 (10) aadA2 Streptomycin 2 (3) aadA5 Streptomycin 34 (59) ant(3'')-Ih Streptomycin/spectinomycin 20 (34) aph(3'')-Ib Streptomycin 5 (9) aph(3')-Ia Kanamycin 2 (3) aph(6)-Id Streptomycin 50 (86) strA Streptomycin 50 (86) strB Streptomycin 50 (86) Multidrug Efflux Pumps acrF Multidrug efflux 58 (100) emrD Multidrug efflux 58 (100) emrE Multidrug efflux 6 (10) mdtM Multidrug efflux 46 (79) β-lactam Resistance blaCMY-18 Cephalosporin 6 (10) blaCTX-M-15 Cephalosporin 26 (45) blaCTX-M-155 Cephalosporin 1 (2) blaCTX-M-159 Cephalosporin 1 (2) blaCTX-M-182 Cephalosporin 1 (2) blaCTX-M-27 Cephalosporin 3 (5) blaCTX-M-3 Cephalosporin 1 (2) blaEC-15 Cephalosporin 20 (34) blaEC-18 Cephalosporin 2 (3) blaEC-19 Cephalosporin 23 (40) blaEC-5 Cephalosporin 7 (12) blaEC-8 Cephalosporin 3 (5) blaEC β-lactam 3 (5) blaLAP-2 β-lactam 4 (7) blaOXA-1 Cephalosporin 21 (36) blaOXA-10 Cephalosporin 2 (3) blaOXA-9 β-lactam 2 (3) blaTEM-1 β-lactam 43 (74) blaTEM-113 Cephalosporin 1 (2) blaTEM-150 β-lactam 1 (2) blaTEM-209 β-lactam 2 (3) blaTEM-214 β-lactam 1 (2) blaTEM-235 β-lactam 1 (2) Chloramphenicol Resistance catA1 Chloramphenicol 11 (19) catA2 Chloramphenicol 2 (3) catB3 Chloramphenicol 21 (36) cmlA Chloramphenicol 1 (2) cmlA1 Chloramphenicol 1 (2) cmlA5 Chloramphenicol 2 (3) TMP/SMX Resistance dfrA1 Trimethoprim 2 (3) dfrA12 Trimethoprim 2 (3) dfrA14 Trimethoprim 9 (16) dfrA15 Trimethoprim 1 (2) dfrA17 Trimethoprim 35 (60) dfrA5 Trimethoprim 1 (2) dfrA7 Trimethoprim 4 (7) dfrA8 Trimethoprim 8 (14) sul1 Sulfonamide 39 (67) sul2 Sulfonamide 51 (88) sul3 Sulfonamide 1 (2) Quinolone Resistance qnrB1 Quinolone 1 (2) qnrS1 Quinolone 5 (9) Other Antimicrobials arr-2 Rifamycin 2 (3) aar-3 Rifamycin 1 (2) erm(B) Macrolide 1 (2) fosA3 Fosfomycin 1 (2) mph(A) Macrolide 37 (64) mph(B) Macrolide 1 (2) qacL Quaternary Ammonium 1 (2) sat2_gen Streptothricin 2 (3) tet(A) Tetracycline 30 (52) tet(B) Tetracycline 21 (36)

β-Lactam and ESBL resistance

We identified 23 genes associated with β-lactam resistance, including 10 ESBL genes (Table 4). Extended-spectrum β-lactamases included bla, bla, bla, bla, bla, bla, bla, bla, bla and bla. Forty-eight out of 58 (83%) isolates carried at least one ESBL gene, and a total of 40 (69%) isolates carried more than one ESBL gene. The presence of any ESBL gene was associated with phenotypic resistance to ceftriaxone (P=0.004). Fifteen isolates with an ESBL gene retained phenotypic susceptibility to ceftriaxone by disc diffusion. All of these isolates each had only one of the following ESBL genes: bla, bla, bla. The most common ESBL gene detected was bla, which occurred in 26 (44.8%) isolates (Table 5). Presence of the bla gene was associated with ceftriaxone resistance, with all 26 isolates being resistant to ceftriaxone by disc diffusion. The bla gene was found in isolates of eight different sequence types, most commonly ST131 [10 out of 19 isolates (52.6%)] and ST410 [8 out of 9 (88.9%) isolates]. We identified 15 O25b:H4-ST131 isolates, of which 10 (66%) had the bla gene. In ST131, the bla gene was highly associated with a chromosomal location with eight isolates (80%) having chromosomal copies, one isolate had a plasmid copy and one isolate with the gene in both locations. ST410 had a very different distribution with six of the eight isolates (75%) containing the bla gene in a plasmid-mediated copy, while only a single isolate had a chromosomal copy and a single isolate had it in both locations.
Table 5.

Characteristics of CTX-M-15 associated isolates and ceftriaxone disk diffusion results

Isolate

Year Collected

Source

Sequence Type (ST)

Plasmid Inclusion Group(s)

Disk Diffusion Result

Location of Gene

1

2018

Urine

131

incB/O/K/Z

R

Genomic

2

2017

Blood

648

incF

R

Genomic

3

2018

Urine

410

incF

R

Plasmid

5

2018

Blood

9398

incHI2, incY

R

Plasmid

10

2018

Body Fluid

410

incF

R

Plasmid

11

2017

Urine

410

incF

R

Plasmid

12

2017

Urine

410

incF

R

Both

14

2014

Pus

410

incF, incY

R

Plasmid

15

2018

Urine

410

incF

R

Plasmid

18

2018

Body Fluid

410

incF

R

Genomic

22

2018

Blood

38

incF

R

Plasmid

25

2014

Urine

131

incF

R

Genomic

26

2014

Urine

131

incF

R

Plasmid

27

2015

Urine

617

incF

R

Both

28

2014

Urine

617

incF, incN

R

Plasmid

30

2016

Urine

131

incF

R

Genomic

34

2016

Urine

410

incF

R

Plasmid

41

2013

Blood

131

incN

R

Genomic

44

2013

Urine

131

incF

R

Genomic

46

2013

Urine

131

incF

R

Genomic

48

2014

Blood

131

incF

R

Genomic

49

2013

Blood

131

incF

R

Genomic

50

2013

Joint Fluid

44

incF

R

Plasmid

51

2013

Genital Swab

131

incF

R

Both

53

2015

Blood

93

incI-1I, incF

R

Plasmid

54

2013

Cerebrospinal Fluid

617

incF

R

Plasmid

Characteristics of CTX-M-15 associated isolates and ceftriaxone disk diffusion results Isolate Year Collected Source Sequence Type (ST) Plasmid Inclusion Group(s) Disk Diffusion Result Location of Gene 1 2018 Urine 131 incB/O/K/Z R Genomic 2 2017 Blood 648 incF R Genomic 3 2018 Urine 410 incF R Plasmid 5 2018 Blood 9398 incHI2, incY R Plasmid 10 2018 Body Fluid 410 incF R Plasmid 11 2017 Urine 410 incF R Plasmid 12 2017 Urine 410 incF R Both 14 2014 Pus 410 incF, incY R Plasmid 15 2018 Urine 410 incF R Plasmid 18 2018 Body Fluid 410 incF R Genomic 22 2018 Blood 38 incF R Plasmid 25 2014 Urine 131 incF R Genomic 26 2014 Urine 131 incF R Plasmid 27 2015 Urine 617 incF R Both 28 2014 Urine 617 incF, incN R Plasmid 30 2016 Urine 131 incF R Genomic 34 2016 Urine 410 incF R Plasmid 41 2013 Blood 131 incN R Genomic 44 2013 Urine 131 incF R Genomic 46 2013 Urine 131 incF R Genomic 48 2014 Blood 131 incF R Genomic 49 2013 Blood 131 incF R Genomic 50 2013 Joint Fluid 44 incF R Plasmid 51 2013 Genital Swab 131 incF R Both 53 2015 Blood 93 incI-1I, incF R Plasmid 54 2013 Cerebrospinal Fluid 617 incF R Plasmid

Fluoroquinolone resistance

We extracted the sequence of the gyrA gene from each isolate and translated them into protein sequences. We examined these for the presence of gyrA mutations that have previously been described in Malawi [27]. We identified the S83L mutation in 24 isolates and the D87N mutation in 22 isolates. In all cases, the D87N mutation co-occurs with the S83L mutation; in only two cases was a single mutation (S83L) observed. In addition, we identified the qnrB1 gene and the qnrS1 gene in 1 (2%) and 5 (9%) of isolates, respectively. These genes did not co-occur in isolates with gyr mutations.

Aminoglycoside resistance

We identified 13 genes associated with aminoglycoside resistance in these isolates (Table 4). Several genes were associated with gentamicin resistance by disc diffusion, aac(3)-IIa (P<0.001), aac(3)-IId (P<0.001), and ant(3″)-Ih (P=0.004). We also detected strA or strB in combination in 50 of the isolates, as has been seen in southern Malawi previously [27]. When found together, these genes confer resistance to streptomycin, which is used in tuberculosis therapy in Africa [47].

Resistance to other antimicrobials

We identified six genes associated with chloramphenicol resistance, the most common being catA1 in 11 (19%) of isolates and catB3 in 21 (36%) of isolates. We did not identify isolates with floR, which has previously been identified in southern Malawi [27]. Detection of catA1 was associated with intermediate susceptibility or resistance to chloramphenicol by disc diffusion (P=0.004), but detection of catB3 was not (P=0.613). We identified 11 genes associated with resistance to TMP-SMX, the most common being the trimethoprim resistance gene dfrA17 (60% of isolates) and the sulfonamide resistance genes sul1 (67% of isolates) and sul2 (88% of isolates). Of these three genes, only sul2 detection was associated with TMP-SMX intermediate susceptibility or resistance by disc diffusion (P=0.025); all isolates that were phenotypically intermediate or resistant to TMP-SMX had sul1 and/or sul2. We detected sul1 and sul2 in 35 of the 58 isolates. Finally, we identified a handful of resistance genes to other antimicrobials, including rifamycin, macrolides, fosfomycin, and tetracyclines (Table 4). Interestingly, the most common AMR genes detected were multidrug efflux pumps, acrF and emrD, both of which occurred in all isolates.

Plasmid incompatibility group

We identified eight different plasmid incompatibility groups (Table 6). The most common were incF incompatibility groups, at least one variant of which (incFIA/incFIB/incFII) was found in all but seven isolates (88%). Although the majority of ST131 were in this group, it was not associated with ST131 (P=0.567) as many non-ST131 isolates had incF incompatibility groups as well. Please see Table S6 for all inc type combinations.
Table 6.

Prevalence of plasmid incompatibility groups

Plasmid Incompatibility Group

Number of isolates, n (%)

incFII

26 (45)

incFIA

19 (33)

incFIB

15 (26)

incY

4 (7)

incB/O/K/Z

2 (3)

incI

2 (3)

incI1-I

2 (3)

incN

2 (3)

Prevalence of plasmid incompatibility groups Plasmid Incompatibility Group Number of isolates, n (%) incFII 26 (45) incFIA 19 (33) incFIB 15 (26) incY 4 (7) incB/O/K/Z 2 (3) incI 2 (3) incI1-I 2 (3) incN 2 (3)

Virulence genes

In total, we identified 37 virulence genes (Table 7) with each isolate carrying a median of seven genes (IQR 3–10). The virulence factors spanned a range of functions, including acid resistance, adhesion, invasins, metalloproteases, and toxins. The most common gene detected was gad, which occurred in all 58 isolates and encodes glutamate decarboxylase, an enzyme linked with bacterial ability to resist environmental stresses [48]. Multiple adhesin proteins were also identified. The most common of these were papC, papH, papG-II, and IpfA. papC (36% of isolates), papH (35% of isolates), papG-II (35% of isolates) are all involved in pili function. IpfA encodes the long polar fimbriae associated with human diarrheal disease, and occurred in 19 of 58 isolates [49]. A single protectin encoded by iss was identified and was the second most common virulence factor identified in 35 of 58 isolates. The iss (increased serum survival) gene was first identified in a human septicemic isolate and was associated with a 20-fold increase in complement resistance and a 100-fold increase in virulence toward 1-day-old chicks [50-52]. Multiple siderophores were identified, with the most common being iha, occurring in 29 of 58 isolates [53]. We also identified two common toxins, sat which occurred in 23 of 58 isolates and senB in 22 of 58 isolates. The secreted autotransporter toxin (sat) appears to fall within one subgroup of autotransporters recently classified as the serine protease autotransporters of (SPATE) family. It acts as a vacuolating cytotoxin for bladder and kidney epithelial cells [54]. The senB gene encodes the TieB protein, which may have some role in enterotoxicity of EIEC [55, 56].
Table 7.

Prevalence of virulence genes identified

Category

Gene

Isolate, n (%)

Acid resistance

gad*

58 (100)

Adhesin

afaC

13 (22)

air

9 (16)

lpfA

19 (33)

nfaE

13 (22)

papA

1 (2)

papC

21 (36)

papE

2 (3)

papG-II

20 (35)

papG-III

1 (2)

papH

20 (35)

sfaF

3 (5)

sfaS

1 (2)

Effector (T3SS)

espl

1 (2)

Invasin

ibeA

1 (2)

Metalloprotease

sslE

23 (40)

Microcin

mchB

2 (3)

mchC

3 (5)

mchF

6 (10)

mcmA

3 (5)

Protectin

iss

35 (60)

Regulator

eilA

9 (16)

Siderophore

iha

29 (50)

ireA

6 (10)

iroN

8 (13)

iutA

3 (5)

Toxin

cma

1 (2)

cnf1

6 (10)

hly-alpha

9 (16)

pic

1 (2)

sat

23 (40)

senB

22 (38)

tsh

1 (2)

vat

6 (10)

Transferase

capU

7 (12)

ATP-binding cassette transporter

ybtP

20 (35)

ybtQ

22 (38)

*This gene is almost universal to E.coli and can be found in non-pathogenic strains.

Prevalence of virulence genes identified Category Gene Isolate, n (%) Acid resistance gad* 58 (100) Adhesin afaC 13 (22) air 9 (16) lpfA 19 (33) nfaE 13 (22) papA 1 (2) papC 21 (36) papE 2 (3) papG-II 20 (35) papG-III 1 (2) papH 20 (35) sfaF 3 (5) sfaS 1 (2) Effector (T3SS) espl 1 (2) Invasin ibeA 1 (2) Metalloprotease sslE 23 (40) Microcin mchB 2 (3) mchC 3 (5) mchF 6 (10) mcmA 3 (5) Protectin iss 35 (60) Regulator eilA 9 (16) Siderophore iha 29 (50) ireA 6 (10) iroN 8 (13) iutA 3 (5) Toxin cma 1 (2) cnf1 6 (10) hly-alpha 9 (16) pic 1 (2) sat 23 (40) senB 22 (38) tsh 1 (2) vat 6 (10) Transferase capU 7 (12) ATP-binding cassette transporter ybtP 20 (35) ybtQ 22 (38) *This gene is almost universal to E.coli and can be found in non-pathogenic strains.

Discussion

In this study, we sequenced 58 isolates collected at a tertiary care centre in Lilongwe, Malawi between 2012–2018. To our knowledge, this is one of the first studies from Malawi demonstrating the feasibility of performing all steps of the whole genome sequencing process, including DNA extraction, library preparation, and the sequencing itself, on site in a local laboratory. Relatively little data exist concerning the genomics of in Africa to date [21-24]. The isolates sequenced as part of our project collected in Lilongwe, in the central region of Malawi, are highly phylogenetically similar to those seen in a previous study conducted in Blantyre, Malawi, in the southern region [27]. Similarly to the previous report, we identified a diverse set of AMR genes, with similar genes occurring across a range of lineages in Malawi. We also provide additional information on common virulence genes associated with in Malawi, many of which are shared across a range of lineages. In this joint phylogenetic analysis, we combined nanopore-only assembled genomes with solely short-read-based assemblies. This approach has the potential to introduce biases in both gene prediction and single-nucleotide polymorphisms due to the divergent error profiles of the two technologies. Nanopore sequencing in particular is known to suffer from a relatively high error rate among raw reads that is dominated by short insertions and deletions and primarily in homopolymer stretches [57]. Although we sequenced to sufficient depth that the vast majority of these errors were eliminated during the consensus generation and multiple polishing steps that produced the final assembly, undoubtedly there existed some residual errors above the rate typically observed with short-read sequencing platforms like Illumina [58]. Where these platform-specific errors are shared among samples sequenced using the same platform, there is the possibility of these segregating biases making their way into the predicted phylogeny. While we observe appropriate clustering of clades by sequence type regardless of sequencing approach (Fig. 2), there is, in several cases, apparent segregation of samples within STs (notably ST131) that is consistent with either true phylogenetic structure or segregating sequencing platform-specific biases. Since the samples collected in our study and the previous study [27] are separated both temporally and geographically, it is reasonable to expect within-ST variation to be attributable to segregating biological variation, but we cannot conclusively rule out that sequencing bias contributes to this phenomenon without careful manual inspection of the segregating sites. Consistent with the Blantyre study’s findings [27], we show that is highly diverse, with a distribution of STs similar to global isolates. Importantly, the previous study utilized samples collected between 1996 and 2014, allowing temporal comparisons between studies as the majority of samples in our analysis were collected after 2013. Our results indicate that ST 131 has become more prevalent (14.9% increasing to 32.8%) and that the bla gene is occurring at a higher frequency (21.3% increasing to 44.8%) in the intervening years. This is consistent with global trends that indicate that the highly drug-resistant ST131, associated with the bla gene, has been increasing in prevalence [9–11, 15–18] As expected, there is some subtle structure within ST131, with isolates from this study being primarily localized on a branch with a longer internal branch length (Fig. 2). Another difference from previous work is the higher number of ST410 isolates in this study, which carried the bla gene at the highest frequency of all the sequence types. Overall, there does not appear to be any strong associations between overall pattern of AMR gene content, virulence gene content, isolation site, and ST within the isolates (Fig. 1), similarly to previous results [27]. Although globally there is a strong association between ST131 and presence of the bla gene, here we identified the bla gene across a diverse set of lineages [11]. This finding is similar to those from other studies in Tanzania and Malawi, where the bla gene was found across numerous STs [22, 27]. We see the bla gene in eight different sequence types, including ST131. The ST that most commonly contained the bla gene was ST410. All of the ST131 isolates that contained the bla gene were O25b:H4-ST131 in this study. Overwhelmingly, the ST131 isolates were clade C, containing the fimH30 gene, consistent with the global expansion of ST131-H30 [12]. Interestingly, there is a strong association between ST and where the bla gene is carried in the ST131 and ST410 isolates. ST131 was much more likely to have a genomic location for the gene, whereas ST410 more frequently carried the gene on a plasmid. This may have implications for how the bla gene spreads in Malawi. Given the diverse lineages that carry the bla gene, additional studies are needed to better understand the epidemiology of this gene in Malawi. Overall, the patterns of AMR gene prevalence were similar to the one previous report from southern Malawi. sul2, strA, strB, dfrA, bla, and sul1 genes remained very common in the population. Interestingly, chloramphenicol resistance gene prevalence was lower than previously reported, with a decrease in the prevalence of catA from 64.9 % to 22 % [27]. This potentially reflects decreased use of the drug in the community with changing treatment guidelines and increasing availability of alternative agents with fewer side effects [46]. Most resistance genes were detected broadly across different genotypes in this study (Fig. 1). In summary, we confirm that the population in Malawi is highly diverse, with evidence for increasing prevalence of the ST131 group in the country. We see a higher proportion of ST 131 isolates and a higher prevalence of the bla gene in our isolates, which were collected a few years later than those described in previous reports. This expansion is consistent with the global increase in O25b:H4-ST131 bearing the fimH30 gene. genotypes are similar between two major tertiary care hospitals that are quite distant, with highly related isolates being found between the sites. As previously seen, AMR genes, including the bla gene, are broadly contained across sequence types. A high diversity of virulence genes were seen within isolates. These data were collected by conducting ONT sequencing in Malawi, highlighting the possibility of conducting rapid longitudinal genomic epidemiology studies of consequential bacteria in sub-Saharan Africa where the sequencing is conducted on site. Click here for additional data file. Click here for additional data file.
  50 in total

1.  Identification of Escherichia coli genes associated with urinary tract infections.

Authors:  Bin-Hsu Mao; Yung-Fu Chang; Joy Scaria; Chih-Ching Chang; Li-Wei Chou; Ni Tien; Jiunn-Jong Wu; Chin-Chung Tseng; Ming-Cheng Wang; Chao-Chin Chang; Yuan-Man Hsu; Ching-Hao Teng
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

Review 2.  Antimicrobial resistance: a global multifaceted phenomenon.

Authors:  Francesca Prestinaci; Patrizio Pezzotti; Annalisa Pantosti
Journal:  Pathog Glob Health       Date:  2015-09-07       Impact factor: 2.894

3.  Minimap2: pairwise alignment for nucleotide sequences.

Authors:  Heng Li
Journal:  Bioinformatics       Date:  2018-09-15       Impact factor: 6.937

4.  Further characterization of complement resistance conferred on Escherichia coli by the plasmid genes traT of R100 and iss of ColV,I-K94.

Authors:  M M Binns; J Mayden; R P Levine
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

5.  Evolution of the iss gene in Escherichia coli.

Authors:  Timothy J Johnson; Yvonne M Wannemuehler; Lisa K Nolan
Journal:  Appl Environ Microbiol       Date:  2008-02-15       Impact factor: 4.792

6.  Bacterial Isolates and Antibiotic Sensitivity among Gambian Children with Severe Acute Malnutrition.

Authors:  Uduak A Okomo; Danlami Garba; Augustin E Fombah; Ousman Secka; Usman N A Ikumapayi; Jacob J Udo; Martin O C Ota
Journal:  Int J Pediatr       Date:  2011-07-14

7.  SRST2: Rapid genomic surveillance for public health and hospital microbiology labs.

Authors:  Michael Inouye; Harriet Dashnow; Lesley-Ann Raven; Mark B Schultz; Bernard J Pope; Takehiro Tomita; Justin Zobel; Kathryn E Holt
Journal:  Genome Med       Date:  2014-11-20       Impact factor: 11.117

8.  Roary: rapid large-scale prokaryote pan genome analysis.

Authors:  Andrew J Page; Carla A Cummins; Martin Hunt; Vanessa K Wong; Sandra Reuter; Matthew T G Holden; Maria Fookes; Daniel Falush; Jacqueline A Keane; Julian Parkhill
Journal:  Bioinformatics       Date:  2015-07-20       Impact factor: 6.937

9.  Genomic landscape of extended-spectrum β-lactamase resistance in Escherichia coli from an urban African setting.

Authors:  Patrick Musicha; Nicholas A Feasey; Amy K Cain; Teemu Kallonen; Chrispin Chaguza; Chikondi Peno; Margaret Khonga; Sarah Thompson; Katherine J Gray; Alison E Mather; Robert S Heyderman; Dean B Everett; Nicholas R Thomson; Chisomo L Msefula
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

10.  Bacteremia Among Febrile Patients Attending Selected Healthcare Facilities in Ibadan, Nigeria.

Authors:  Oluwafemi Popoola; Aderemi Kehinde; Veronica Ogunleye; Oluwafemi J Adewusi; Trevor Toy; Ondari D Mogeni; Eunice O Aroyewun; Sarah Agbi; Olukemi Adekanmbi; Akinlolu Adepoju; Sufiyan Muyibi; Ini Adebiyi; Oluseyi O Elaturoti; Chukwuemeka Nwimo; Hadizah Adeoti; Temitope Omotosho; Olabisi C Akinlabi; Paul A Adegoke; Olusoji A Adeyanju; Ursula Panzner; Stephen Baker; Se Eun Park; Florian Marks; Iruka N Okeke
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

View more
  2 in total

1.  Comparing Long-Read Assemblers to Explore the Potential of a Sustainable Low-Cost, Low-Infrastructure Approach to Sequence Antimicrobial Resistant Bacteria With Oxford Nanopore Sequencing.

Authors:  Ian Boostrom; Edward A R Portal; Owen B Spiller; Timothy R Walsh; Kirsty Sands
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

2.  Whole-Genome Sequencing-Based Antimicrobial Resistance Characterization and Phylogenomic Investigation of 19 Multidrug-Resistant and Extended-Spectrum Beta-Lactamase-Positive Escherichia coli Strains Collected From Hospital Patients in Benin in 2019.

Authors:  Carine Laurence Yehouenou; Bert Bogaerts; Sigrid C J De Keersmaecker; Nancy H C Roosens; Kathleen Marchal; Edmond Tchiakpe; Dissou Affolabi; Anne Simon; Francis Moise Dossou; Kevin Vanneste; Olivia Dalleur
Journal:  Front Microbiol       Date:  2021-12-09       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.